GUILD Learning and Development has developed an online course titled Saxenda (liraglutide) for the management of obesity: A guide for community pharmacists, which was sponsored by Novo Nordisk.
This course examines the clinical findings of Saxenda in the management of obesity and outlines the key counselling points that pharmacists should provide to patients prescribed Saxenda.
This prescription-only product is approved as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with obesity (BMI 30 kg/m2) or who are overweight (BMI 27 kg/m2) in the presence of at least one weight-related comorbid condition.
This course is suitable for inclusion in a CPD plan.
Access at myCPD.org.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Jun 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Jun 18
